← Leaderboards
Oreola Donini
Soligenix, Inc.
$1,916,410
Attributed
$1,916,410
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $829.7K · FY2013–22$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$1,916,410 · 3
By mechanism
R44$1,466,410 · 1
R43$450,000 · 2
Top collaborators
No co-investigators on record.
Most similar at Soligenix, Inc.
Same institution · by research overlap
- Richard Conrad Straube$3,189,817
Others in their field
Top investigators on “Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$677,505,141
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$532,027,174
- Barton F Haynes · Duke University$497,761,007
- Jeffrey P Krischer · University Of South Florida$397,532,270
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
Research focus
ResponseFundingProgramsSymptomsInfectionClinical DevelopmentFuturePopulations At RiskSafetyClinical ResearchRequest For ProposalsNonhuman PrimateAluminum SulfateCoronavirusCost EffectiveClinical TrialsAttenuatedComparativeCoupledAntiviral TherapyCellsCellular ImmunityAdjuvantAntigens
Grant awards (4)
Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP$829,746
R44 · FY2022 · AI · contact PI
Thermostabilized Subunit Glycoprotein Vaccine Platform: Immune Characterization of an Emulsified Adjuvant with SARS-CoV-2 Spike Protein and EBOV GP$636,664
R44 · FY2021 · AI · contact PI
"Dusquetide for the treatment of oral mucositis in the pediatric population"$150,000
R43 · FY2019 · DE · contact PI
Beclomethasone post exposure therapy for gastrointestinal acute radiation syndrom$300,000
R43 · FY2013 · AI · contact PI